AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18834464 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 66
Study 16440209 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEO) 0.625 mg daily
Number of subjects: 10739
Study 16440209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 14514742 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate PD fluid (34 mM pure bicarbonate at neutral pH)
Number of subjects: 28
Study 14514742 — intervention group
Group type: COMPARATOR
Intervention: Lactate PD fluid (35 mM lactate)
Number of subjects: 28
Study 10962221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine added to fluphenazine decanoate and benztropine
Number of subjects: 0
Study 10962221 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis
Number of subjects: 0
Study 10962221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant medication
Number of subjects: 0
Study 8793416 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated fatty acids (PUFA)
Number of subjects: 75
Study 8793416 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in saturated fatty acids (SAFA)
Number of subjects: 75
Study 8793416 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in PUFA
Number of subjects: 75
Study 8793416 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in SAFA
Number of subjects: 75
Study 1613811 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside treatment
Number of subjects: 0
Study 1613811 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 0
Study 6488704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tar cigarette with nicotine yield of 0.55 mg (LN)
Number of subjects: 9
Study 6488704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tar cigarette with nicotine yield of 0.90 mg (MN)
Number of subjects: 9
Study 6488704 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual brand cigarette
Number of subjects: 9
Study 6488704 — intervention group
Group type: COMPARATOR
Intervention: All cigarette types
Number of subjects: 9
Study 30269876 — intervention group
Group type: EXPERIMENTAL
Intervention: RFM care package intervention
Number of subjects: 409175
Study 30269876 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 409175
Study 27841024 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MI-Exercise)
Number of subjects: 11
Study 27841024 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-Intensity Exercise (HI-Exercise)
Number of subjects: 11
Study 27841024 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 11
Study 24824051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment snack with education messages
Number of subjects: 1284
Study 24824051 — intervention group
Group type: COMPARATOR
Intervention: Education messages alone (Control)
Number of subjects: 1284
Study 22298552 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Delton Plus FS+)
Number of subjects: 39
Study 22298552 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GC Fuji Triage White)
Number of subjects: 39
Study 20956409 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal corticosteroid therapy
Number of subjects: 2104
Study 20956409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2104
Study 18942420 — intervention group
Group type: EXPERIMENTAL
Intervention: Viferon
Number of subjects: 101
Study 18942420 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 101
Study 18942420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 15329600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.09, 0.24, 0.54, and 1.23 ng/ml)
Number of subjects: 0
Study 15329600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (13.4, 33.8, 67.8, and 126.1 ng/ml)
Number of subjects: 0
Study 15329600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12038744 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research approach
Number of subjects: 0
Study 9641851 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (30 patients)
Number of subjects: 40
Study 9641851 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 40
Study 9641851 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (9 patients with EMG+ response)
Number of subjects: 40
Study 7982345 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional methods of positive-pressure ventilation
Number of subjects: 0
Study 7982345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid and hemodynamic support strategies
Number of subjects: 0
Study 7982345 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer pharmacologic agents
Number of subjects: 0
Study 2518989 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational counselling to lose weight, hypocaloric diet, and motivational support; followed for a mean period of 239 days.
Number of subjects: 155
Study 2518989 — intervention group
Group type: COMPARATOR
Intervention: Usual types of management (control group).
Number of subjects: 155
Study 2518989 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (educational counselling).
Number of subjects: 155
Study 326641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0
Study 326641 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 29603130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - home-based program using a flow-resistive inspiratory loading device, training twice a day at high intensity for 2 weeks or longer until surgery
Number of subjects: 241
Study 29603130 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241
Study 29603130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 241
Study 26943711 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday sleep debt
Number of subjects: 593
Study 24899130 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft (bioactive porous Poly dl-lactide-co-glycolide scaffolds with antibiotic gentamicin and crosslinked gelatin)
Number of subjects: 0
Study 24899130 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft
Number of subjects: 0
Study 22237870 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula with 10(6) CFU Bb12/g (PRO)
Number of subjects: 172
Study 22237870 — intervention group
Group type: COMPARATOR
Intervention: Partially hydrolyzed whey formula (CON)
Number of subjects: 172
Study 20737608 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM (Global System for Mobile Communications, 900 MHz and 1,800 MHz) base station signals
Number of subjects: 397
Study 20737608 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 397
Study 18423901 — intervention group
Group type: EXPERIMENTAL
Intervention: Unobserved dosing
Number of subjects: 119
Study 18423901 — intervention group
Group type: COMPARATOR
Intervention: Observed dosing
Number of subjects: 119
Study 15746667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 microg initially followed by 100 microg in each subsequent dose)
Number of subjects: 204
Study 15746667 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (25 microg in each dose)
Number of subjects: 204
Study 15746667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 204
Study 15746667 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 204
Study 12933402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 0.1 mg/kg
Number of subjects: 43
Study 12933402 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 2 micro g/kg
Number of subjects: 43
Study 12933402 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 43
Study 11103227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofu (290 g daily)
Number of subjects: 42
Study 11103227 — intervention group
Group type: COMPARATOR
Intervention: Meat (150 g lean meat daily)
Number of subjects: 42
Study 8624148 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% tretinoin cream
Number of subjects: 22
Study 8624148 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 22
Study 1728202 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 24
Study 6700383 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly intra‐muscular injections of 7.5 to 10 megaunits of interferon/m2
Number of subjects: 6
Study 6700383 — intervention group
Group type: COMPARATOR
Intervention: Daily injections of interferon
Number of subjects: 6
Study 31813508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement (PVR)
Number of subjects: 657
Study 30394493 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy, mean duration 10.1±3.9 days
Number of subjects: 38
Study 30394493 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 38
Study 26856289 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Optic White WT
Number of subjects: 80
Study 26856289 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Pro‐Health Whitening WT
Number of subjects: 80
Study 26856289 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm and Hammer Advance White Extreme Whitening WT
Number of subjects: 80
Study 26856289 — intervention group
Group type: COMPARATOR
Intervention: Control (brushed with water without WT)
Number of subjects: 80
Study 24910196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridaemic waist phenotype
Number of subjects: 517
Study 22929964 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (250 or 500 ml of a milk whey based green tea containing soft drink)
Number of subjects: 12
Study 22929964 — intervention group
Group type: COMPARATOR
Intervention: Milk whey based soft drink without green tea (control)
Number of subjects: 12
Study 20042421 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D AutoLVQ software
Number of subjects: 103
Study 17563741 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) with marrow purged with 4 hydroperoxycyclophosphamide
Number of subjects: 137
Study 17563741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive timed induction therapy
Number of subjects: 137
Study 17563741 — intervention group
Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 137
Study 15649852 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 microg bid
Number of subjects: 13
Study 15649852 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 microg bid
Number of subjects: 13
Study 15649852 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (orally dose titrated slow‐release)
Number of subjects: 13
Study 15649852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11803253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor-permeable article
Number of subjects: 0
Study 11803253 — intervention group
Group type: COMPARATOR
Intervention: Vapor-impermeable article
Number of subjects: 0
Study 9951784 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and calcitriol supplements
Number of subjects: 49
Study 9951784 — intervention group
Group type: COMPARATOR
Intervention: No supplements
Number of subjects: 49
Study 7762059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and Prednisone (Pred) with Pred withdrawal
Number of subjects: 120
Study 7762059 — intervention group
Group type: COMPARATOR
Intervention: Conversion from CsA to Azathioprine (Aza-Pred)
Number of subjects: 120
Study 3297230 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 61
Study 3297230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycone-papaverine (5 mg + 50 mg)
Number of subjects: 61
Study 31689141 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (TM-group) with follow-up every 3 months and monthly telemedicine support.
Number of subjects: 483
Study 31689141 — intervention group
Group type: COMPARATOR
Intervention: 3-month follow-up (3M-group).
Number of subjects: 483
Study 31689141 — intervention group
Group type: COMPARATOR
Intervention: 1-month follow-up (1M-group).
Number of subjects: 483
Study 31689141 — intervention group
Group type: EXPERIMENTAL
Intervention: TM-group and 1M-group patients with poor adherence at baseline.
Number of subjects: 483
Study 31689141 — intervention group
Group type: COMPARATOR
Intervention: 3M-group patients with poor adherence at baseline.
Number of subjects: 483
Study 30541634 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (evidence-based decision aid about mammography screening)
Number of subjects: 426
Study 30541634 — intervention group
Group type: COMPARATOR
Intervention: Active control (information about home safety)
Number of subjects: 426
Study 27595728 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA cream
Number of subjects: 140
Study 27595728 — intervention group
Group type: EXPERIMENTAL
Intervention: Local pressure
Number of subjects: 140
Study 27595728 — intervention group
Group type: COMPARATOR
Intervention: 20% benzocaine gel
Number of subjects: 140
Study 27595728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 26583142 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover training
Number of subjects: 60
Study 26583142 — intervention group
Group type: COMPARATOR
Intervention: Stabilometric platform training
Number of subjects: 60
Study 23559150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 23559150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20951147 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5mg/day)
Number of subjects: 63
Study 20951147 — intervention group
Group type: COMPARATOR
Intervention: Control (no risedronate)
Number of subjects: 63
Study 20951147 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5mg/day) and Control
Number of subjects: 63
Study 19058068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer psychoeducational intervention (OCPI) - 4 sequential, structured, in-person educational sessions
Number of subjects: 33
Study 19058068 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 20562702 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-242 1.2 mg/kg/day
Number of subjects: 274
Study 20562702 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-242 2.4 mg/kg/day
Number of subjects: 274
Study 20562702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 15684116 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (60 mg/kg daily for 10 days)
Number of subjects: 512
Study 15684116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 15684116 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Placebo
Number of subjects: 512
Study 11925355 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of thyroxine daily
Number of subjects: 446
Study 11925355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study 9426384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat area of the fourth scan (L2-L3)
Number of subjects: 23
Study 9426384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat area of the third scan (L1-L2)
Number of subjects: 23
Study 9426384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat areas of the sixth and seventh scans (L4-L5)
Number of subjects: 23
Study 7895394 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training twice a week for 3 months
Number of subjects: 40
Study 7895394 — intervention group
Group type: COMPARATOR
Intervention: Home training after 2 hours of instruction
Number of subjects: 40
Study 3075410 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of tripamide
Number of subjects: 159
Study 3075410 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of hydrochlorothiazide
Number of subjects: 159
Study 11307810 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (1-2 microg/kg/min)
Number of subjects: 24
Study 11307810 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (higher doses)
Number of subjects: 24
Study 11307810 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-therapy (argatroban and warfarin)
Number of subjects: 24
Study 31048415 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (0.8 mg/kg)
Number of subjects: 201
Study 31048415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 30172765 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical navigation
Number of subjects: 20
Study 30172765 — intervention group
Group type: COMPARATOR
Intervention: Control (no surgical navigation)
Number of subjects: 20
Study 27212102 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 74
Study 27212102 — intervention group
Group type: COMPARATOR
Intervention: No resurfacing
Number of subjects: 74
Study 25416486 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home counselling intervention using the APN-BQ Instrument
Number of subjects: 206
Study 23075570 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge from hospital after 3 days inpatient treatment with home visits by generic community nurses
Number of subjects: 139
Study 23075570 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 139
Study 19858233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eight biomarkers (von Willebrand factor antigen, surfactant protein D, tumor necrosis factor receptor‐1, interleukin [IL]‐6, IL‐8, intercellular adhesion molecule‐1, protein C, plasminogen activator inhibitor‐1) and clinical predictors (APACHE III, organ failures, age, underlying cause, alveolar‐arterial oxygen gradient, plateau pressure)
Number of subjects: 549
Study 19858233 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors alone (APACHE III, organ failures, age, underlying cause, alveolar‐arterial oxygen gradient, plateau pressure)
Number of subjects: 549
Study 19858233 — intervention group
Group type: EXPERIMENTAL
Intervention: Best performing biomarkers (neutrophil chemotactic factor, IL‐8, and surfactant protein D)
Number of subjects: 549
Study 17885562 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg daily
Number of subjects: 382
Study 17885562 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine 20 mg twice daily
Number of subjects: 382
Study 15699722 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniett device treatment (pressure pulses at 6 Hz for 0.6 seconds, oscillating between 0.4 and 1.2 kPa)
Number of subjects: 40
Study 15699722 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniett device treatment
Number of subjects: 40
Study 12084604 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular CRT
Number of subjects: 41
Study 12084604 — intervention group
Group type: EXPERIMENTAL
Intervention: Univentricular CRT
Number of subjects: 41
Study 12084604 — intervention group
Group type: EXPERIMENTAL
Intervention: First treatment (both methods pooled)
Number of subjects: 41
Study 12084604 — intervention group
Group type: EXPERIMENTAL
Intervention: Second treatment (both methods pooled)
Number of subjects: 41
Study 9700176 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation
Number of subjects: 64
Study 9700176 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 64
Study 7638950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (1 mg) with metoclopramide (10 mg)
Number of subjects: 34
Study 7638950 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg) with metoclopramide (10 mg)
Number of subjects: 34
Study 2495710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (1 mg/kg bolus over 10 minutes followed by 1.5 mg/kg/hr for 1 hour and then 0.25 mg/kg/hr for 24 hours)
Number of subjects: 29
Study 2495710 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (3 bolus doses: 0.5 mg followed after 6 and 12 hours by 0.25 mg)
Number of subjects: 29
Study 2495710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 29
Study 2495710 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 29
Study 972015 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy started within two months of oophorectomy
Number of subjects: 0
Study 972015 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy started after three years post-oophorectomy
Number of subjects: 0
Study 972015 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed estrogen replacement therapy started after six years post-oophorectomy
Number of subjects: 0
Study 972015 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients post-oophorectomy
Number of subjects: 0
Study 30653528 — intervention group
Group type: EXPERIMENTAL
Intervention: High construal level condition combined with high social distance condition
Number of subjects: 197
Study 30653528 — intervention group
Group type: EXPERIMENTAL
Intervention: High construal level with high social distance
Number of subjects: 197
Study 30653528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two high construal level approaches
Number of subjects: 197
Study 28705454 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg ATLG
Number of subjects: 175
Study 28705454 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg ATLG
Number of subjects: 175
Study 25226850 — intervention group
Group type: EXPERIMENTAL
Intervention: QAX576 (6 mg/kg)
Number of subjects: 23
Study 25226850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24429201 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor or H2 blocker
Number of subjects: 242
Study 24429201 — intervention group
Group type: COMPARATOR
Intervention: No anti-acid treatment
Number of subjects: 242